文献速递造血干细胞移植与细胞治疗血栓与止血

人类与非人灵长类动物肾异种移植后凝血反应的特征——一篇叙述性综述

Characterizing coagulation responses in humans and nonhuman primates following kidney xenotransplantation-A narrative review.
PubMed 文献 · Am J Hematol · 2024-10-15

该叙述性综述总结了活体人类首次猪肾移植背景下,肾异种移植中凝血失调的三大机制:猪血管性血友病因子(vWF)与人类血小板相互作用、猪血栓调节蛋白激活人类蛋白C效率低下、以及猪移植物血栓性微血管病和受者全身消耗性凝血病;并讨论通过基因工程改造猪vWF、表达人类血栓调节蛋白和内皮蛋白C受体及药物干预来纠正凝血失调。

要点

  • 猪vWF与人类血小板相互作用可诱导异常凝血反应,增加移植物失败风险。
  • 猪血栓调节蛋白激活人类蛋白C效率低下,种属特异性差异加剧凝血障碍。
  • 猪移植物可发生血栓性微血管病,受者可出现全身消耗性凝血病。

核心结论

  • 理解和控制凝血失调对于推进异种移植成为终末期肾病患者可行治疗选择至关重要。

研究设计与样本

  • 叙述性综述,总结人类与非人灵长类动物肾异种移植后凝血反应的相关文献。

主要发现

  • 猪vWF与人类血小板相互作用可诱导异常凝血反应,增加移植物失败风险。
  • 猪血栓调节蛋白激活人类蛋白C的效率低下,种属特异性差异加剧凝血挑战。
  • 猪移植物中可发生血栓性微血管病,受者中可出现全身消耗性凝血病。
  • 凝血失调主要源于内皮细胞反应差异以及猪与人类凝血-抗凝血通路的不相容性。

关键数值与推荐

  • 通过修饰猪vWF以及在猪细胞中表达人类血栓调节蛋白和内皮蛋白C受体,可作为使两个物种凝血系统更接近的策略性干预。
  • 对器官来源猪进行基因工程改造以及给予多种药物有助于纠正凝血失调。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent report of the first pig kidney transplant in a living human brings hope to thousands of people with end-stage kidney failure. The scientific community views this early success with caution as kidney xenotransplantation exhibits many challenges and barriers. One of these is coagulation dysregulation. This includes (i) pig von Willebrand Factor (vWF) interaction with human platelets, which can induce abnormal clotting responses, heightening the risk of graft failure, (ii) the inefficiency of pig thrombomodulin in activating human protein C, which emphasizes the species-specific variations that aggravate coagulation challenges, and (iii) the development of thrombotic microangiopathy in the pig grafts and the occurrence of systemic consumptive coagulopathy in the recipients. Indeed, coagulation dysregulation largely results from differences in endothelial cell response and incompatibilities between pig and human coagulation-anticoagulation pathways. These barriers can be resolved by modifications to pig vWF and the expression of human thrombomodulin and endothelial protein C receptors in pig cells, serving as strategic interventions to align the coagulation systems of the two species more closely. These coagulation challenges have clinical implications in how they affect graft survival and patient outcome. Genetic engineering of the organ-source pig and the administration of various drugs have assisted in correcting this coagulation dysregulation. Hence, comprehending and controlling coagulation dysregulation is crucial for progress in xenotransplantation as a viable option for treating patients with terminal kidney disease.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zidan A, El-Sherbini AH, Noureldin A, et al. Characterizing coagulation responses in humans and nonhuman primates following kidney xenotransplantation-A narrative review. Am J Hematol. 2024. PMID: 39404060. doi:10.1002/ajh.27506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。